vs
Side-by-side financial comparison of Grace Therapeutics, Inc. (GRCE) and Medicus Pharma Ltd. (MDCX). Click either name above to swap in a different company.
Delix Therapeutics is an American biotech company based in Boston, Massachusetts. The company develops novel neuroplasticity-promoting therapeutics for central nervous system (CNS) diseases such as depression and post-traumatic stress disorder (PTSD). It was co-founded in 2019 by David E. Olson and Nick Haft.
GRCE vs MDCX — Head-to-Head
Income Statement — Q3 FY2022 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $0 | $11.6K |
| Net Profit | $-3.8M | $-20.9M |
| Gross Margin | — | — |
| Operating Margin | — | -0.1% |
| Net Margin | — | -180917.3% |
| Revenue YoY | — | -79.2% |
| Net Profit YoY | -17.3% | -818.7% |
| EPS (diluted) | $-0.09 | $-1.12 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | — | $11.6K | ||
| Q2 25 | — | $40.0K | ||
| Q3 24 | — | $55.5K | ||
| Q4 21 | $0 | — |
| Q3 25 | — | $-20.9M | ||
| Q2 25 | — | $-6.2M | ||
| Q3 24 | — | $-2.3M | ||
| Q4 21 | $-3.8M | — |
| Q3 25 | — | -0.1% | ||
| Q2 25 | — | -15038.7% | ||
| Q3 24 | — | -4204.8% | ||
| Q4 21 | — | — |
| Q3 25 | — | -180917.3% | ||
| Q2 25 | — | -15438.7% | ||
| Q3 24 | — | -4104.8% | ||
| Q4 21 | — | — |
| Q3 25 | — | $-1.12 | ||
| Q2 25 | — | $-0.43 | ||
| Q3 24 | — | $-0.24 | ||
| Q4 21 | $-0.09 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $46.3M | $8.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $111.1M | $-910.1K |
| Total Assets | $114.2M | $10.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $8.7M | ||
| Q2 25 | — | $9.7M | ||
| Q3 24 | — | — | ||
| Q4 21 | $46.3M | — |
| Q3 25 | — | $-910.1K | ||
| Q2 25 | — | $3.2M | ||
| Q3 24 | — | $4.8M | ||
| Q4 21 | $111.1M | — |
| Q3 25 | — | $10.0M | ||
| Q2 25 | — | $11.9M | ||
| Q3 24 | — | — | ||
| Q4 21 | $114.2M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-4.6M | $-6.8M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $-6.8M | ||
| Q2 25 | — | $-5.5M | ||
| Q3 24 | — | — | ||
| Q4 21 | $-4.6M | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
